ADC Therapeutics news

ADC Therapeutics

ADC Therapeutics' IFRS loss for 3 months of 2022 was $16.661 million, down 3.1 times from $51.527 million in the previous year. Revenues were $46.498 million. The company did not generate revenues a year earlier.

ADC Therapeutics

ADC Therapeutics' GAAP loss for 2021 was $230.026 million, down 6.6% from $246.29 million the previous year. Revenue was $33.917 million; the company earned no revenue last year.

ADC Therapeutics

ADC Therapeutics' IFRS loss for 9M 2021 was $195.645 million, up 2.8% from $190.361 million in the prior year. Revenue was $16.907 million. A year earlier company did not receive revenue.

ADC Therapeutics

ADC Therapeutics' IFRS loss for 6 months of 2021 was $124.096 million, down 27% from $170.033 million in the prior year. Revenues were $3.76 million. A year earlier, the company did not generate revenues.

ADC Therapeutics

ADC Therapeutics' IFRS loss for 3 months of 2021 was $51.527 million, up 18.5% from $43.476 million in the prior year.

ADC Therapeutics

ADC Therapeutics has received FDA approval for Zynlonta. It is intended to treat patients with relapsed or refractory large cell lymphoma after specific systemic therapy.

ADC Therapeutics

ADC Therapeutics loss under IFRS for 2020 was $246.29 million, up 2.1 times from $116.484 million in the previous year.

ADC Therapeutics

ADC Therapeutics' IFRS loss in 9 months. In 2020, the loss was $190.361 million, up 2.3 times from $81.199 million in the previous year. The Group did not receive any revenue in the reporting period. A year earlier, it was $2.34 million.

ADC Therapeutics

ADC Therapeutics' IFRS loss for 6 months of 2020 amounted to $170,033 mln, a 3-fold increase from $49,858 mln in the previous year. The company did not receive any revenue in the reporting period. A year earlier, it was $2.34 mln.